NEWS

WIRES

OTHER

TPI Ships Macrolide API Samples for International Sales Standard Testing

This is the first step for the development of macrolide international export business for TPI following the signing of the sales and marketing agreement with RELATIONS International Ltd., a Bangladesh corporation that specializes in API product sales in the People's Republic of Bangladesh, in June this year.

Jiangchuan Macrolide facility (JCM) currently has an active production license for manufacturing Azithromycin API (H10970072). Additional information regarding JCM can be found at www.sfda.gov.cn (Chinese version).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: http://www.tianyinpharma.com.

About RELATIONS International Ltd.

RELATIONS International Ltd. (RELATIONS), founded in 1978, incorporated in the People's Republic of Bangladesh, is located at Motijheel Commercial Area, Dhaka-1000, Bangladesh. It specializes in the sales of APIs and other medical/pharmaceutical products in Bangladesh. RELATIONS client base includes Sandoz - Austria, Spain, Italy, Germany & India, Sifavitor, ABC Farmaceutici, Solmag, Recordati, SIMS, Farchemia and Archimia etc of Italy, Kirsch, CF Budenheim, Peter-Greven of Germany, Viscose Closures of UK, Fuji Kasei, Kyowa Hakko and Kaneka of Japan. RELATIONS also established a number of business relations with Chinese manufactures including TPI.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tianyinpharma.com

Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

SOURCE Tianyin Pharmaceutical Co., Inc.